Pay in 4 interest-free payments of $6.73 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Absence of a documented problem is not the same as evidence of benefit
1 In the REIMAGINE 2 trial, the most commonly reported AEs were GI-related, occurring in 405/603 (67.2%) participants in the CagriSema 2.4 mg/2.4 mg group, 326/605 (53.9%) participants in the semaglutide 2.4 mg group, 60/152 (39.5%) participants in the cagrilintide 2.4 mg group, 329/594 (55.4%) participants in the CagriSema 1 mg/1 mg group, 288/608 (47.4%) participants in the semaglutide 1 mg group, and 42/149 (28.2%) participants in the placebo group
The thigh: This is the most common site used by people who are self- administrating the injections, or giving an injection to an infant or a small child
Zaki et al., 2021)
US$ 27.41
US$ 23.71
US$ 24.44
US$ 27.50
US$ 26.19
US$ 21.89
